HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Volume 20, Volume 2, February 2016 Biomedical Research Governance       » Tissue banking in Singapore — An Evolving Enterprise       » China Recognizes Prominent Scientists and Stresses on Innovation       » NUS Researchers Uncover Potent Parasite-killing Mechanism of Nobel Prize-Winning Anti-Malarial Drug       » A New Water Robot "Born" to Detect Water Quality       » Probing the Mystery of How Cancer Cells Die       » Researchers Find Link between Processed Foods and Autoimmune Diseases       » Unravelling the Genetics of Pregnancy and Heart Failure      
INSIDE INDUSTRY
Lantheus Medical Imaging and FUJIFILM RI Pharma renew long-term license and distribution agreement
Lantheus Medical Imaging, Inc., a leader in developing, manufacturing and distributing innovative diagnostic imaging agents, has entered into a new agreement with FUJIFILM RI Pharma Co., Ltd. (FRI) to license and distribute Cardiolite ® (Kit for the Preparation of Technetium Tc99m Sestamibi for Injection) and Neurolite ® (Kit for the Preparation of Technetium Tc99m Bicisate for Injection) in Japan. Under the terms of the 10-year agreement effective January 1, 2013, which immediately follows an earlier 10-year agreement with FRI, Lantheus will continue to supply FRI with Cardiolite ® and Neurolite ® in finished form as well as provide the raw materials to manufacture and sell the products in unit dose form. Cardiolite ® and Neurolite ® are technetium-based radiopharmaceutical imaging agents used in single-photon emission computed tomography (SPECT).

“We are pleased to continue our long-term collaborative relationship with FRI, which we’ve successfully developed over the past ten years,” said Don Kiepert, President and Chief Executive Officer, Lantheus Medical Imaging.“ Japan represents one of the largest markets for imaging agents worldwide. As such, we share a joint commitment with FRI to provide proven, reliable medical imaging technologies to healthcare providers and patients. This commitment includes ensuring continued access to Cardiolite ® and Neurolite ® for SPECT imaging.”

“Lantheus is the ideal partner for FRI in the Japanese diagnostic imaging market as we have a shared view of the clinical value and benefits of radiopharmaceuticals in the diagnosis of disease,” said Yoshiro Kumano, President and Chief Executive Officer, FRI. “Our customers are our top priority, and we will continue to meet their needs by offering Cardiolite ® and Neurolite ® for use in cardiovascular and brain imaging, respectively.”

Click here for the complete issue.

NEWS CRUNCH  
news EmTech Asia Opens: Features 50 speakers on innovation and emerging technologies
news Russia's only project to supply local high-tech anti-cancer drugs abroad continues with the first shipment to Vietnam
news Wheat Genome Sequencing Gets Major Boost
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  

Primates in Biomedical Research
COLUMNS  
\
APBN Editorial Calendar 2016
January:
Guest Editorial - Biotechnology In Korea
February:
Guest Editorial - Biomedical Research Governance
March:
Guest Editorial - Life-Saving Opportunities: A Guide to Regenerative Medicine
April:
Cancerology / Oncology
May:
Guest Editorial - Antibody Informatics In Japan
June:
Medical Devices and Technology
July:
Water Technology
August:
Occupational Health
September:
Olympics: Evolution of Sports
October:
Respiratory: Seasonal flu viruses
November:
Tobacco Smoking
Editorial calendar is subjected to changes.
– Editor: Carmen, Jia Wen Loh
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» Editorial Enquiries: biotech_edit@wspc.com
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   Ms PoPo Kwok or Ms Sok Ching Lim/td>
Copyright© 2015 World Scientific Publishing Co Pte Ltd  •  Privacy Policy